SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development
The pandemic of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been posing great threats to the world in many aspects. Effective therapeutic and preventive approaches including drugs and vaccines are still unavailable although they are in development. Comprehensive unders...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-11-01
|
| Series: | Frontiers in Cellular and Infection Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2020.587269/full |
| _version_ | 1819060719402876928 |
|---|---|
| author | Mei-Yue Wang Rong Zhao Li-Juan Gao Xue-Fei Gao De-Ping Wang Ji-Min Cao |
| author_facet | Mei-Yue Wang Rong Zhao Li-Juan Gao Xue-Fei Gao De-Ping Wang Ji-Min Cao |
| author_sort | Mei-Yue Wang |
| collection | DOAJ |
| description | The pandemic of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been posing great threats to the world in many aspects. Effective therapeutic and preventive approaches including drugs and vaccines are still unavailable although they are in development. Comprehensive understandings on the life logic of SARS-CoV-2 and the interaction of the virus with hosts are fundamentally important in the fight against SARS-CoV-2. In this review, we briefly summarized the current advances in SARS-CoV-2 research, including the epidemic situation and epidemiological characteristics of the caused disease COVID-19. We further discussed the biology of SARS-CoV-2, including the origin, evolution, and receptor recognition mechanism of SARS-CoV-2. And particularly, we introduced the protein structures of SARS-CoV-2 and structure-based therapeutics development including antibodies, antiviral compounds, and vaccines, and indicated the limitations and perspectives of SARS-CoV-2 research. We wish the information provided by this review may be helpful to the global battle against SARS-CoV-2 infection. |
| first_indexed | 2024-12-21T14:31:28Z |
| format | Article |
| id | doaj.art-95a257057d124975ac01a87ae4f10079 |
| institution | Directory Open Access Journal |
| issn | 2235-2988 |
| language | English |
| last_indexed | 2024-12-21T14:31:28Z |
| publishDate | 2020-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cellular and Infection Microbiology |
| spelling | doaj.art-95a257057d124975ac01a87ae4f100792022-12-21T19:00:28ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882020-11-011010.3389/fcimb.2020.587269587269SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics DevelopmentMei-Yue WangRong ZhaoLi-Juan GaoXue-Fei GaoDe-Ping WangJi-Min CaoThe pandemic of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been posing great threats to the world in many aspects. Effective therapeutic and preventive approaches including drugs and vaccines are still unavailable although they are in development. Comprehensive understandings on the life logic of SARS-CoV-2 and the interaction of the virus with hosts are fundamentally important in the fight against SARS-CoV-2. In this review, we briefly summarized the current advances in SARS-CoV-2 research, including the epidemic situation and epidemiological characteristics of the caused disease COVID-19. We further discussed the biology of SARS-CoV-2, including the origin, evolution, and receptor recognition mechanism of SARS-CoV-2. And particularly, we introduced the protein structures of SARS-CoV-2 and structure-based therapeutics development including antibodies, antiviral compounds, and vaccines, and indicated the limitations and perspectives of SARS-CoV-2 research. We wish the information provided by this review may be helpful to the global battle against SARS-CoV-2 infection.https://www.frontiersin.org/articles/10.3389/fcimb.2020.587269/fullsevere acute respiratory syndrome coronavirus 2protein structureantibodiesantiviral compoundsvaccines |
| spellingShingle | Mei-Yue Wang Rong Zhao Li-Juan Gao Xue-Fei Gao De-Ping Wang Ji-Min Cao SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development Frontiers in Cellular and Infection Microbiology severe acute respiratory syndrome coronavirus 2 protein structure antibodies antiviral compounds vaccines |
| title | SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development |
| title_full | SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development |
| title_fullStr | SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development |
| title_full_unstemmed | SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development |
| title_short | SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development |
| title_sort | sars cov 2 structure biology and structure based therapeutics development |
| topic | severe acute respiratory syndrome coronavirus 2 protein structure antibodies antiviral compounds vaccines |
| url | https://www.frontiersin.org/articles/10.3389/fcimb.2020.587269/full |
| work_keys_str_mv | AT meiyuewang sarscov2structurebiologyandstructurebasedtherapeuticsdevelopment AT rongzhao sarscov2structurebiologyandstructurebasedtherapeuticsdevelopment AT lijuangao sarscov2structurebiologyandstructurebasedtherapeuticsdevelopment AT xuefeigao sarscov2structurebiologyandstructurebasedtherapeuticsdevelopment AT depingwang sarscov2structurebiologyandstructurebasedtherapeuticsdevelopment AT jimincao sarscov2structurebiologyandstructurebasedtherapeuticsdevelopment |